Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Central Line Complication Clear all
Active, not recruiting Phase 3 Interventional

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180
View directory record Official record
Conditions
Cervical Cancer
Interventions
Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
38
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Withdrawn Phase 3 Interventional

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

NCT01284205
View directory record Official record
Conditions
Bladder Cancer
Interventions
Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
14
States / cities
Laguna Hills, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jul 23, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT02655016
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
47
States / cities
Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Active, not recruiting Not applicable Interventional

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04646226
View directory record Official record
Conditions
End-Stage Kidney Disease, Hemodialysis Complication
Interventions
AV graft, surgical intervention for creation of a fistula
Device · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Completed No phase listed Observational

Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

NCT01988766
View directory record Official record
Conditions
Thrombosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

NCT00719264
View directory record Official record
Conditions
Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma, Hypernephroid
Interventions
RAD001(everolimus), interferon alfa-2a, bevacizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

NCT01379534
View directory record Official record
Conditions
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
21
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jul 23, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703
View directory record Official record
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
18
States / cities
Miami Beach, Florida • West Palm Beach, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Glue Versus Suture for Securing Radial Arterial Lines

NCT06589284
View directory record Official record
Conditions
Arterial Catheters, Catheter Related Complication
Interventions
Silk 0-0 suture covered by chlorhexidine gluconate dressing, 2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing
Procedure
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Not applicable Interventional

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

NCT00964093
View directory record Official record
Conditions
Central Line Bloodstream Infections
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Central Line Placement-EVALUATION OF LINE DEPTH AS A FACTOR IN NEED FOR LINE REPLACEMENT SECONDARY TO MALPOSITION

NCT02602665
View directory record Official record
Conditions
Vascular Access Complication
Interventions
Shallow catheter tip placement, Deep catheter tip placement
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

NCT00718523
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479, AMG 479 Placebo
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
23
States / cities
Alhambra, California • Burbank, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Jul 23, 2026, 11:15 AM EDT
Completed No phase listed Observational

Comprehensive Evaluation of a Central Line Simulation Course

NCT01165398
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
Not listed
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Ben-Guard Garment in Reducing Pediatric Central Line Complications

NCT05109338
View directory record Official record
Conditions
Central Venous Catheters
Interventions
Ben-Guard Garment
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 10 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Dynamic Haptic Robotic Trainer (DHRT) and DHRT+ for Central Venous Catherization Insertion Training for Surgical Residents

NCT04541446
View directory record Official record
Conditions
Central Line Complication, Central Line Infection
Interventions
Dynamic Haptic Robotic Trainer (DHRT), Advanced Dynamic Haptic Robotic Trainer (DHRT+)
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Completed Not applicable Interventional Results available

The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants

NCT00593684
View directory record Official record
Conditions
Prematurity, Very Low Birth Weight
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
Up to 72 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 11:15 AM EDT
Not listed Not applicable Interventional

Umbilical Cord Care for the Prevention of Colonization

NCT01893060
View directory record Official record
Conditions
Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 23, 2026, 11:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

NCT01342172
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 23, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558
View directory record Official record
Conditions
Ovarian Neoplasms, Ovarian Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
11
States / cities
Miami Beach, Florida • Orlando, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Recruiting Phase 4 Interventional

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

NCT06412120
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Niraparib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Withdrawn Not applicable Interventional

Novel Strategy to Encourage Early Removal of Central Venous Catheters

NCT04136561
View directory record Official record
Conditions
Vascular Access Complication, Central Line Complication, Central Line-Associated Infection, Superficial Vein Thrombosis, Deep Vein Thrombosis
Interventions
Midline catheter
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 23, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Active, not recruiting Not applicable Interventional

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

NCT05703269
View directory record Official record
Conditions
NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma, Brain Metastases, Adult, Non-small Cell Lung Cancer, SCLC, Small-cell Lung Cancer
Interventions
single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
34
States / cities
Savannah, Georgia • Decatur, Illinois • Effingham, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 11:15 AM EDT
Terminated Not applicable Interventional Results available

Innovative Central Line Securement Device in the Pediatric Population

NCT04522778
View directory record Official record
Conditions
Central Line Complication, Central Line Infection, Central Line-Associated Infection, Central Line Sepsis, Short Gut Syndrome, Quality of Life, Pediatric Disorder
Interventions
Wearable Central Line Securement Device (Vest), Traditional Securement Dressing
Device · Other
Lead sponsor
Ryan St. Pierre-Hetz
Other
Eligibility
0 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 23, 2026, 11:15 AM EDT